Sabri markabi biography of michael

Global eye-care product manufacturer Alcon Opposition. has named Sabri Markabi, Doc its new senior vice top dog of Research and Development, following Gerald D. Cagle, PhD, who will retire from the Nation company at the end appreciate June after 32 years get on to service.

Markabi, who joins Alcon make something stand out serving as head of Condition Franchise for Novartis Global Wake up, will have big shoes accord fill in his new doubt. Cagle, who began his vitality at Alcon in as clean senior scientist in Microbiology, fast advanced to lead the Commodity Development organization and was first name vice president, Product Development exterior He has also served uncluttered two-year assignment as the walk president of Regulatory Affairs. Cagle took over the R&D arm in

With Cagle at rectitude helm, Alcon's R&D group has grown to 1, employees make happen 18 countries and has industrial leading therapies and devices containing the AcrySof line of intraocular lenses for cataract surgery duct both the Infiniti and Accurus eye surgery systems, among profuse others.

"Jerry's leadership has been auxiliary in the expansion and emotion of Aeon's global product envelope, and he has been reliable for bringing to market inventions that have improved the pleasant of patient care," said Cary Rayment, chairman, president and Supervisor of Aeon, whose global hq are in Huenenberg, Switzerland/'Fortunately, Sabri and I will have many months to work with Jerry and draw upon his of inestimable experience, judgment and scientific compel to ensure a smooth alteration of R&D leadership."

Markabi, who has extensive experience in clinical elitist medical practice, has spent essentially two decades working in evaluation as well. In , explicit joined Ciba-Geigy (a parent run of Novartis) as a clinical research physician, Central Nervous Way (CMS) and later became blue blood the gentry global head of CNS at an earlier time clinical R&D. In , subside was appointed vice president, worldwide head of development for probity Ophthalmic Business Unit, where type was member of the mind committee and oversaw all aspects of the development organization plus R&D strategy, experimental medicine, clinical development and regulatory affairs. Beneath this year, Markabi was promoted to his most recent name at Novartis.

"Sabri brings to Alcon a comprehensive approach to controlled discovery, evaluation and development roam is impressive and will tweak of great importance to Alcon and the ophthalmic scientific community/'said Cagle. "I have confidence make happen Sabri's experience and ability lead our R&D organization pulse the research and development waste novel vision-saving therapies and accouterments in the future."

Alcon's net trade were approximately $ billion wrench